As Humira plummets, AbbVie dials up Rinvoq and Skyrizi estimates to a combined $27B

As AbbVie slogs through sharp revenue declines for Humira, the company is looking to the immunology light at the end of the tunnel.

During the final quarter of 2023, sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion globally. The rate of erosion seems to have gathered steam in the fourth quarter and outpaced the med's full-year sales decline of around 32%.